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Abstract 
Objectives: TNF! blockade is an effective therapy for rheumatoid arthritis 
(RA). Immunomodulatory effects of TNF! antagonists are thought to contribute to their 
therapeutic action. Here, we investigated whether anti-TNF! therapeutics exerted their 
immunoregulatory effects through modulation of dendritic cell (DC) function.  
Methods: Two complementary approaches were taken: In the first ‘in vitro’ 
approach monocyte-derived DC from healthy donors were matured with LPS and 
treated with TNF! antagonists in vitro for 48 hours. In the second ‘ex vivo’ approach 
monocyte-derived DC were generated from RA patients before and 8-12 weeks into 
anti-TNF! treatment. DC were analysed for survival, phenotype, cytokine production 
and T cell stimulatory capacity.  
Results:  TNF! blockade during DC maturation in vitro induced approximately 
40 % of DC to undergo apoptosis. Importantly, the surviving DC displayed a semi-
mature phenotype with reduced levels of HLA-DR, CD80, CD83, CD86 and CCR7, and 
their production of IL-10 was enhanced as compared to DC matured without 
TNF!"antagonists. Furthermore, anti-TNF!-treated DC were poor stimulators of T cell 
proliferation and polarised T-cell development towards a higher IL-10/lower IFN-# 
cytokine profile. Similarly, DC derived from RA patients after anti-TNF! treatment 
showed impaired upregulation of CD80 and CD86 upon LPS activation and displayed 
poor T cell stimulatory activity.  
Conclusions: Our data show that TNF! blockade has profound effects on DC 
function with downstream, potentially immunoregulatory, effects on T-cells. These data 
provide an interesting new insight into the potential mechanism by which anti-TNF! 
drugs contribute to the restoration of immunoregulation in RA patients.  
Introduction 
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic 
synovitis, causing cartilage and bone destruction [1]. Although the precise aetiology of 
RA is unknown, recent genetic data clearly implicate T-cells in its pathogenesis [2, 3]. 
Additionally, tumor necrosis factor-! (TNF!) has been identified as a key mediator of 
synovial inflammation [4]. Therapeutic blockade of TNF! with neutralising antibodies 
(e.g. infliximab) or soluble TNF! receptor Ig constructs (e.g. etanercept) provides 
significant beneficial clinical effects in approximately 60% of RA patients [5].  
 Anti-TNF! therapeutics target inflammation at multiple levels (reviewed in [6]). 
For instance, they inhibit the induction of pro-inflammatory IL-1 and IL-6 [7, 8]; 
downregulate cartilage-destroying matrix metalloproteinases [9]; reduce recruitment of 
inflammatory cells to the synovium [10-12], and inhibit angiogenesis [13]. 
Immunomodulatory effects of TNF! antagonists have also been reported but remain 
largely unexplained. For instance, anti-TNF! therapeutics can reverse T-cell anergy 
[14], restore regulatory T-cell function in RA patients [15, 16] and reduce Th17 
responses in the skin of psoriasis patients [17]. 
 Dendritic cells (DC) are professional antigen presenting cells that regulate T-cell 
responses. DC have been implicated in RA pathogenesis. Myeloid DC with high T-cell 
stimulatory capacity are enriched in synovial tissue of RA patients [18-20]. It is thought 
that presentation of arthritogenic antigens to T-cells by these DC contributes to 
perpetuation of the inflammatory autoimmune response [21, 22]. TNF! plays a central 
role in DC biology. It is a classical DC maturation factor, enhancing the expression of 
MHC II and co-stimulatory molecules (e.g. CD80, CD86) [23]. TNF! also promotes 
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DC survival [24, 25]. The maturation status and survival of DC are both important 
factors that determine the balance between immunity and tolerance. Whereas immature 
DC induce T-cell tolerance, mature DC activate T-cells and induce immunity. 
Enhancement of DC survival can break immune tolerance, resulting in autoimmune 
disease [26, 27]. Conversely, ablation of DC abrogates T-cell priming to antigens and 
inhibits autoimmunity [28, 29].  
Considering the key role of TNF! in DC biology, we hypothesised that anti-
TNF! therapy exerts its immunoregulatory effects in RA through modulation of DC 
function. Recent small studies in RA patients reported no effect of TNF! blockade on 
DC cytokine production [30] but a reduction in the DC maturation marker CD83 [31]. 
In contrast, an in vitro study of TNF! blockade during DC differentiation and 
maturation demonstrated no surface phenotype modulation but reduced production of 
IL-1$, IL-6 and several chemokines by mature DCs [32]. In the current study we have 
investigated the effects of TNF! blockade during DC maturation with the toll-like 
receptor 4 (TLR4)-ligand lipopolysaccharide (LPS). TLR4 ligands are enhanced in 
serum and synovial fluid of RA patients and are thought to contribute to DC activation 
and breakdown of tolerance in RA [33]. We have also studied the ex vivo generation of 
monocyte-derived DC from RA patients receiving anti-TNF! therapies. Our data 
suggest that, under both circumstances, TNF! blockade endows reduced T cell 
stimulatory properties on the DC, potentially contributing to the immunoregulatory 
effects of these drugs. 
Materials and Methods 
Ethics
Peripheral blood samples were obtained with informed consent and following approval 
by the Newcastle and North Tyneside Research Ethics Committee 2.  
Generation of monocyte-derived dendritic cells 
DC were generated from peripheral blood as described previously [34]. Briefly, 
peripheral blood mononuclear cells were isolated by density gradient centrifugation on 
Lymphoprep (Axis-Shield Diagnostics, Dundee, UK). CD14
+
 monocytes were isolated 
by positive magnetic selection using anti-CD14 microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany). To generate immature DC, monocytes were cultured at 0.5x10
6 
cells/ml in the presence of IL-4 and GM-CSF (50 ng/ml each, Immunotools, Friesoythe, 
Germany) for 6 days. All cells were cultured in RPMI-1640 supplemented with 10% 
fetal calf serum (FCS), 2 mM glutamine, 100 U/ml penicillin and 100 "g/ml 
streptomycin at 37
o
C with 5% CO2. Medium supplemented with cytokines was 
refreshed on day 3.  
 
Treatment of dendritic cells with TNF-! antagonists 
Immature DC were washed and re-plated in fresh medium without cytokines at 
0.25x10
6 
cells/ml. DC were left untreated or were matured with lipopolysaccharides 
(LPS from e-coli, Sigma, 100 ng/ml) for 48 h in the absence or presence of a soluble 
TNF-Receptor p55 Ig fusion protein (10 "g/ml) [35], the therapeutic anti-TNF-! 
monoclonal antibody infliximab (10 "g/ml, Schering Plough, USA), or as a control 
human IgG (10 "g/ml, Grifols, Los Angeles, CA, USA). In some experiments dead DC 
were removed by the Annexin V dead cell removal kit (Miltenyi). 
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Apoptosis and cell phenotype analysis by flow cytometry 
DC were washed and incubated with Annexin V-APC and PI in Annexin V binding 
buffer (BD Pharmingen, San Jose, CA, USA) for 15 minutes at room temperature. For 
active caspase-3 intracellular staining, DC were washed and incubated with human IgG 
for 15 minutes on ice, then fixed and permeabilised using Fix/Perm buffer for 20 
minutes on ice, washed twice with BD Perm/Wash buffer, and blocked for 15 minutes 
on ice in 2 % rabbit serum. After blocking, anti active caspase-3 antibody (BD 
Biosciences) was added for 20 minutes at room temperature. For cell surface phenotype 
analysis of DC and T-cells the following mAbs were used: CD25 (clone M-A251), 
CD80 (clone L307.4), CD86 (clone 2331), CD83 (clone HB15e), HLA-DR (clone 
L243) (all from BD Pharmingen) and CCR7 (clone 150503, R&D Systems). Cells were 
washed and incubated with mAbs in PBS with 3% FCS, 2 mM EDTA and 0.01% 
sodium azide for 20 minutes on ice in the presence of human IgG. Cell viability was 
assessed using Via-Probe (BD Pharmingen). Intracellular FoxP3 was detected using a 
FoxP3-APC staining kit (PCH101; eBioscience San Diego, CA, USA). Data were 
collected on a Becton Dickinson FACScan and analysed using FlowJo (Treestar, USA).   
 
DC cytokine production 
DC were stimulated at 2x10
5
 DC/ml with CD40-ligand transfected J558L mouse cells 
(kindly provided by Peter Lane, Birmingham University, UK) at a 1:1 ratio. After 24 h, 
IL-10 and TNF-! in supernatants were quantified by sandwich ELISA (BD 
Pharmingen). 
 
DC-T-cell cultures 
T-cells were isolated from peripheral blood using CD3-negative selection with the 
RosetteSep T-cell enrichment cocktail (Stem Cell Technologies, Canada). DC were co-
cultured with allogeneic CD3
+
 T cells at a 1:10 ratio, unless otherwise stated. Cytokines 
in supernatants were analysed by ELISA and T-cell proliferation was assessed by 
measuring 
3
H-thymidine incorporation in the last 16 h of culture. In restimulation 
experiments T-cells primed by DC for 6 days were rested for 5 days with 0.1 ng/ml rIL-
2 (kind gift from Prof. John Robinson), washed and restimulated with CD3/CD28 
expander beads (1:1, Dynal). No residual DC were observed in the T-cell cultures prior 
to restimulation. After 72 h, supernatants were harvested. Cytokines in supernatants (IL-
10, IL-4, IFN#%"IL-17) were quantified by sandwich ELISA (BD Pharmingen).  
 
Statistics
Mann Whitney, 2-way ANOVA with Bonferroni posttests and t-tests were performed 
using GraphPad software (San Diego, CA, USA). A p-value <0.05 was considered 
statistically significant with a 95% confidence interval. 
Results
 
TNF! blockade during DC maturation results in apoptosis  
Because DC produce TNF! and other survival factors in response to LPS, the effect of 
TNF! blockade on DC apoptosis after LPS activation was investigated. Two TNF! 
antagonists were used: A soluble TNF-Receptor p55 Ig fusion protein (TNFR) and the 
chimeric anti-TNF! monoclonal antibody infliximab. Both TNF antagonists were used 
at 10 &g/ml because i) this concentration is within the range of anti-TNF serum 
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concentrations found in patients undergoing treatment [6] and ii) in vitro experiments 
with a TNFR1-Fas transfected cell line showed that this concentration effectively 
blocked cell death induced by LPS-activated DC supernatants (data not shown).  
Removal of GM-CSF/IL-4 from immature DC cultures led to high levels of 
apoptosis and cell death within 48 h, as visualised by the high percentage of Annexin 
V
pos
/PI
neg
  (early apoptotic), Annexin V
pos
/PI
pos
 (late apoptotic and dead cells) and active 
caspase-3
pos
 cells (apoptotic cells, Figure 1A and B). LPS activation of immature DC 
rescued a large number of cells from apoptosis, but the addition of TNFR or infliximab 
abrogated this ‘rescue’. Immature DC could also be rescued from apoptosis by addition 
of soluble rTNF! at concentrations produced by DC upon LPS activation (around 10 
ng/ml, data not shown). Control IgG did not affect the level of apoptosis, indicating that 
the effect of the TNF-! antagonists was not mediated through Fc-gamma receptor 
binding. Apoptosis of LPS-activated DC treated with TNFR (LPS-TNFR DC) or 
infliximab (LPS-inflix DC) increased during the 72 hour culture period (Figure 1C). 
These data show that TNF! blockade abrogates the enhanced survival of DC following 
maturation in response to LPS. 
 
TNF! blockade affects phenotype and cytokine production of LPS-activated DC 
To assess modulation of DC maturation by TNF! antagonists, the expression of CD80 
and CD86 (co-stimulatory molecules), CD83 (DC maturation marker), HLA-DR 
(antigen-presenting molecule) and CCR7 (chemokine receptor) was measured. Dead 
cells were excluded from the analysis. CD80, CD86 and CD83 expression were 
significantly reduced by treatment of DC with TNF! antagonists, whereas HLA-DR 
expression was not significantly inhibited (Figure 2A). There was a trend towards 
reduced CCR7 expression after anti-TNF treatment (p=0.057). DC clustering, normally 
observed after LPS activation of DC in vitro, did not occur in the presence of TNF! 
antagonists (Figure 2B).  
Interestingly, upon CD40 ligation LPS-TNFR DC and LPS-inflix DC produced 
significantly higher levels of IL-10 than control DC (LPS-IgG DC), while TNF! levels 
were similar (Figure 2C). These data show that TNF!"blockade during LPS maturation 
results in a DC population with a semi-mature phenotype and substantially enhanced 
IL-10 production. 
 
TNF! antagonists reduce T-cell stimulatory capacity of DC 
We next determined whether the partial maturation of DC treated with TNF! 
antagonists affected their ability to stimulate allogeneic CD3
+
 T-cells. DC treated with 
TNFR or infliximab had a significantly reduced capacity to induce T-cell proliferation 
and IFN# production (Figure 3A and B). The reduced T-cell stimulatory capacity of 
LPS-TNFR and LPS-inflix DC was not simply due to lower levels of live DC in these 
populations, because removal of apoptotic DC did not enhance T-cell proliferation 
(Figure 3C). However, from these experiments it cannot be excluded that apoptotic DC 
may have influenced the maturation of the surviving DC. Nevertheless, together these 
data show that blocking TNF during maturation diminishes the immunostimulatory  
capacity of DC. 
 
Anti-TNF! treated DC modulate cytokine production by T-cells 
To assess whether anti-TNF! treatment of DC affects the ‘quality’ of T-cell responses, 
T-cells expanded by the various DC populations were analysed further. Firstly, the 
group.bmj.com on February 9, 2010 - Published by ard.bmj.comDownloaded from 
 6
expansion of regulatory T-cells was determined by measuring percentages of 
CD25
hi
/Foxp3
pos
 T-cells. FoxP3 was measured 11 days after T cell activation to ensure 
that transient activation-induced FoxP3 expression in non-Treg cells had disappeared 
[36]. Although T-cells primed by anti-TNF!-treated DC (Figure 4A) contained a higher 
percentage of Tregs than T-cells primed by immature DC, the percentages of Tregs 
were similar to the percentages found in T-cell populations primed by mature DC (LPS 
DC or LPS-IgG DC). The data indicate that neutralisation of TNF! during DC 
maturation does not obviously alter the ability of these DC to expand Tregs.    
 Secondly, the polarising activity of anti-TNF! treated DC on T-cell cytokine 
production was investigated. Resting T-cells were recovered from primary DC-T-cell 
cultures and re-stimulated with CD3/CD28 beads. T-cells primed by anti-TNF! DC 
produced significantly higher levels of IL-10, IL-4, and IL-17 but lower levels of IFN# 
than T-cells primed by mature LPS-DC (Figure 4B). These data indicate that anti-TNF! 
treatment of DC affects the ‘quality’ of T-cell responses by skewing their cytokine 
profile, overall favouring anti-inflammatory cytokines. 
Phenotype and function of DC derived from RA patients before and after anti-
TNF! therapy 
To investigate the effects of TNF! blockade on DC from RA patients treated with anti-
TNF drugs, monocyte-derived DC were generated from RA patients ex vivo, before and 
after 8-12 weeks of anti-TNF!"therapy (Adulimumab or Etanercept, see Table 1). No 
anti-TNF! was added to in vitro cultures. LPS-induced upregulation of CD80 and 
CD86 was lower during anti-TNF! therapy in most patients (Figure 5A and B): CD80 
was lower in 3 out of 5 cases and CD86 was lower in 4 out of 4 cases. Furthermore, in 4 
out of 5 cases the T-cell stimulatory capacity of DC during anti-TNF! therapy was 
reduced (Figure 5C) shown by a decreased ability to initiate T-cell proliferation. 
Comparing the cytokine profiles of primed T-cells revealed considerable heterogeneity. 
However, there was a trend towards enhanced IL-10 and reduced IL-4, IFN# and IL-17 
production by T-cells primed by mature DC derived during anti-TNF! therapy (Figure 
5D). These data suggest a reduced T-cell stimulatory capacity of DC derived from RA 
patients on anti-TNF! drugs. However, no association was found between the clinical 
response to anti-TNF! therapy and functional modulation of DC. 
 
Table 1. Rheumatoid arthritis patients on anti-TNF! treatment
Patient
ID
Age Sex Disease 
Duration 
(years)
anti-TNF
Drug
MTX Pred. RhF anti-
CCP
Pre-
treatment
DAS
Post-
treatment
DAS
TNFRA02 40 F 2 Adalimumab 
 
+ – + + 5.27 
 
2.77 
 
TNFRA04 57 M 4 Etanercept 
 
+ – + + 7.17 
 
2.12 
 
TNFRA05 76 F 1 Etanercept 
 
+ + + + 7.46 
 
4.43 
 
TNFRA07 49 F 2.5 Etanercept 
 
+ – – N.D. 7.42 
 
6.77 
 
TNFRA08 40 F 4 Etanercept 
 
+ – – – 7.08 
 
6.34 
 
MTX = methotrexate therapy DAS; Pred. = prednisone therapy; RhF = rheumatoid 
factor; anti-CCP = anti-cyclic citrullinated peptide antibodies; DAS = disease activity 
score; F = female; M = male; N.D. = not determined 
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Discussion
Our experiments demonstrate a profound effect of TNF! blockade on the generation 
and maturation of DC from their myeloid precursors. Our in vitro data clearly indicate 
that blockade of TNF! during final DC maturation results in enhanced DC apoptosis 
and induction of semi-mature DC, with reduced co-stimulatory molecule expression and 
T-cell stimulatory capacity. Importantly, T-cells activated by these semi-mature DC 
produced enhanced levels of anti-inflammatory IL-10 and IL-4 and lower levels of pro-
inflammatory IFN#. It is perhaps surprising that IL-17 levels are modestly but 
significantly increased in these experiments but this could be a downstream 
consequence of reduced IFN#"levels [37, 38]. When we compared monocytes derived 
from RA patients receiving TNF! blockade to cells harvested pre-treatment from the 
same patients we found that, even without adding anti-TNF drugs in vitro, they also 
generated DC with reduced co-stimulatory molecule expression and T-cell stimulatory 
capacity. These effects on DC generation were most likely caused by anti-TNF! 
treatment per se, as RA patients receiving and responding to methotrexate alone did not 
show impaired DC generation or function (data not shown). The question of whether 
anti-TNF modulated DC function through neutralisation of autocrine TNF! and/or via 
reverse signalling was not addressed here, but both mechanisms may be important [6,
39]. 
The difference in IL-17 and IL-4 production between T-cells in our in vitro and 
ex vivo experiments was subtle. Furthermore, these are fundamentally different 
experiments from the perspective of anti-TNF! exposure. In the in vitro experiments 
monocytes develop normally and are only exposed to TNF! blockade during the final 
stages of DC maturation. The ex vivo experiments are complementary because 
monocytes develop in the presence of TNF! blockade, which is absent during DC 
development and maturation. Despite this we can detect an ‘imprinted’ effect of in vivo 
anti-TNF exposure in the ex vivo cultures, with the overall finding of reduced T cell 
stimulatory capacity. Thus, our data suggest an important effect of TNF! on both DC 
precursors and DC. 
Although TNF! blockade was originally viewed as a simple but potent anti-
inflammatory therapy, studies on patients receiving treatment have shown enhancement 
of sub-optimal regulatory T-cell function [15] and the generation of a novel subset of 
regulatory T-cells in association with therapy [16]. Our findings suggest an additional 
mechanism by which anti-TNF! therapy enhances immunoregulation, via the 
generation of ‘semi-mature’ DC that secrete high levels of IL-10 and with the capacity 
to generate T-cells with enhanced anti-inflammatory cytokine secretion. Furthermore, 
by inducing apoptosis in DC during maturation, anti-TNF! therapeutics may also act by 
reducing the strength of the autoimmune response. 
Differences between our data and limited previous reports also attest to the 
critical importance of experimental conditions (e.g. type of anti-TNF! used and time 
point of anti-TNF! exposure) when interpreting similar phenomena. Van Lieshout et al 
[32] cultured monocytes in the presence of a monovalent PEGylated form of p55 TNFr 
(essentially a monomeric form of our sTNFr). In contrast to our data, even after 
maturation with LPS they could not demonstrate a difference in surface phenotype 
compared to conventionally matured DC, although chemokine, IL-1$ and IL-6 
production were reduced when DC from RA patients were matured in the presence of 
this agent. Another study showed that the addition of infliximab at the start of the 
monocyte-derived DC culture period resulted in immature DC with reduced CD1a and 
CD86 expression as well as reduced T-cell stimulatory capacity. These effects were less 
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marked following DC maturation with LPS [40]. Zaba et al [17] used 
immunohistochemistry and real-time PCR of psoriatic skin to demonstrate reduced IL-
23, IL-17 and IFN# levels following etanercept therapy, as well as reduced CD83 and 
DC-LAMP expression by skin DC – data more consistent with our ex vivo findings, 
although it is unclear whether these effects were caused by reduced infiltration of 
inflammatory cells and/or immunomodulation. They also generated immature DC in
vitro in the presence of etanercept, showing reduced CD86 and HLA-DR expression 
and reduced T-cell stimulatory capacity. A further study showed the pro-apoptotic 
effects of etanercept on dermal DC in psoriatic plaques [41], again consistent with our 
observations on DC survival.  
TNF! is a pleiotropic cytokine with acute and chronic effects on many cell types. 
Consequently TNF! blockade, which is widely used to treat active RA, psoriasis and 
inflammatory bowel disease, can no longer be viewed as a purely anti-inflammatory 
therapy [42]. It has pro-apoptotic effects on various cells and has also been shown to 
have immunoregulatory consequences in vivo. To these effects can now be added an 
important modulation of DC survival, phenotype and function. RA is accepted by many 
as an autoimmune disease initiated by inappropriate T-cell responses against self 
antigens and several novel approaches are being developed to target T-cells [43]. 
However, T-cells are instructed in their activities by DC, which therefore have an even 
more pivotal role in the development and control of autoimmunity and thus provide a 
more tempting target. Clinical studies are starting to hint at the potential of TNF! 
blockade to induce remission in the early stages of RA [44] and evolving data, including 
those presented here, suggest mechanism(s) for these therapeutically revolutionary 
observations.  
In conclusion we have adopted two complementary approaches to study the 
effect of TNF! blockade on DC survival, phenotype and function. Whereas DC are 
more likely to die when TNF! is blocked during their maturation, those that survive 
exhibit a semi-mature phenotype and poor T cell stimulatory capacity. In line with this, 
DC derived from RA patients during anti-TNF! therapy have a similar phenotype. 
Incubation of T-cells with anti-TNF!-treated DC skews the T-cell cytokine profile 
towards higher IL-10/lower IFN#"production, potentially contributing to the previously 
demonstrated immunoregulatory effects of TNF! blockade.  
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Figure Legends 
Figure 1.  TNF! blockade during DC maturation results in apoptosis. Immature 
monocyte-derived DC were extensively washed to remove cytokines and re-cultured in 
the absence or presence of LPS (LPS DC), LPS and human IgG (LPS-IgG DC), LPS 
and TNFR (LPS-TNFR DC) or LPS and infliximab (LPS-inflix DC) for 48 h (A, B) or 
for various time periods as indicated (C). Apoptosis was measured using Annexin V/PI 
staining (A) or activated caspase-3 intracellular staining (B, C). Data are representative 
of at least 3 independent experiments. 
 
Figure 2.  TNF! blockade affects phenotype and cytokine production of LPS-
activated DC. Immature monocyte-derived DC were extensively washed to remove 
cytokines and re-cultured in the absence or presence of LPS (LPS DC), LPS and human 
IgG (LPS-IgG DC), LPS and TNFR (LPS-TNFR DC) or LPS and Infliximab (LPS-
Inflix DC) for 48 h. (A). Phenotype of DC was determined by flow cytometry. Debris 
and dead cells were excluded on the basis of the forward scatter, side scatter and 
viability staining using Via-probe. Data from independent experiments are shown and 
were calculated as the fold change compared to LPS-DC. Horizontal lines represent 
median values. (B) Morphology of DC populations as shown by phase contrast 
microscopy (100X). (C) DC were washed to remove TNF! antagonists and stimulated 
with CD40L-expressing cells for 24 h. IL-10 and TNF! levels in supernatants were 
measured by ELISA and expressed as the percentage of cytokine production by LPS DC. 
LPS DC produced 642 ± 476 pg/ml IL-10 and 769 ± 610 pg/ml TNF!. Data of 4 
independent experiments are shown. Horizontal lines represent median values. *p<0.05 
and **p<0.01 as determined by Mann Whitney test. 
 
Figure 3.  DC matured in the presence of TNF! antagonists have low T-cell 
stimulatory capacity. Immature DC or DC activated with LPS (LPS DC), LPS and 
human IgG (LPS-IgG DC), LPS and TNFR (LPS-TNFR DC) or LPS and Infliximab 
(LPS-Inflix DC) for 48 h were washed and co-cultured with allogeneic CD3
+
 T-cells 
(1x10
5
) for 6 days. Proliferation was measured by 
3
H-Thymidine incorporation (A, C) 
and IFN# production in supernatants (using 10x10
3 
DC) was determined by ELISA. (B). 
In some experiments dead cells were removed from the DC populations prior to co-
culture with T-cells (20x10
3
 DC: 1x10
5
 T cells) using the Annexin V dead cell removal 
kit (C). Data are representative of at least 3 independent experiments and are shown as 
mean +/- SEM of triplicate cultures. (A) *p<0.05 indicate significant differences 
between T cell proliferation induced by LPS-IgG DC and LPS-TNFR DC and between 
T cell proliferation induced by LPS-IgG DC and LPS-Inflix DC as determined by 2-way 
ANOVA with Bonferroni posttests. (B, C) *p<0.05 as determined by t-test. NS: not 
significant. 
 
Figure 4.  DC matured in the presence of TNF! antagonists do not preferentially 
expand regulatory T-cells but skew T-cell cytokine profiles. DC activated with LPS 
(LPS DC), LPS and TNFR (LPS-TNFR DC) or LPS and Infliximab (LPS-Inflix DC) for 
48 h were washed and co-cultured with allogeneic CD3
+
 T-cells at a 1:10 ratio. After 6 
days T-cells were recovered and rested for another 5 days with 0.1 ng/ml rIL-2. (A) 
Flow cytometry analysis of CD25 and FoxP3 expression. Debris and dead cells were 
excluded on the basis of the forward scatter, side scatter and viability staining using 
Via-probe. Percentage of FoxP3
+
 cells is indicated in the Figure. Data are representative 
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of at least 3 independent experiments. (B) T-cells primed by DC populations were 
washed and restimulated with CD3/CD28 expander beads. After 72 h supernatants were 
harvested and cytokine levels determined by ELISA. Results on cytokine production by 
T-cells primed by anti-TNF-treated DC (TLPS-TNFR DC or TLPS-Inflix DC) are presented as a 
percentage of cytokine production by T-cells primed by mature DC (TLPS DC). TLPS DC 
produced 361 ± 267 pg/ml IL-10, 253 ± 248 pg/ml IL-4, 20.4 ± 6.6 ng/ml IFN# and 869 
± 699 pg/ml IL-17. Horizontal lines represent median values. p-values were determined 
by Mann Whitney test and indicate significant differences to TLPS DC. 
 
Figure 5.  DC derived from RA patients after anti-TNF! therapy have lower T-cell 
stimulatory capacity. Monocyte-derived DC were generated from the peripheral blood 
of RA patients before (pre) and after taking anti-TNF! antagonists for 8 to 12 weeks 
(post). DC were left immature or were matured with LPS for 24 h. (A, B) Expression of 
co-stimulatory molecules CD80 and CD86 pre and post anti-TNF! therapy. (A) LPS-
induced upregulation of CD80 and CD86 expression was calculated by dividing the 
MFI (median fluorescence intensity) of CD80 or CD86 on LPS-matured DC by the MFI 
of CD80 or CD86 on immature DC, respectively. Results of 5 (CD80) and 4 (CD86) 
independent RA patients are shown. NS: p-values >0.05 as determined by Mann 
Whitney test, indicating non-significant differences between LPS-induced CD80 and 
CD86 expression on DC pre and post anti-TNF-therapy. (B) The CD80 and CD86 flow 
cytometry plots shown are from different RA patients. (C, D) T-cell stimulatory and 
polarising capacities of mature DC pre and post anti-TNF! therapy. Mature DC were 
co-cultured with allogeneic CD3
+
 T-cells at a 1:10 ratio. T-cells from the same donor 
were used for DC derived from RA patients pre and post anti-TNF! therapy. (C) After 
3, 5 and 7 days proliferation was measured by adding 
3
H-Thymidine for 16 hours. Data 
of 5 RA patients are presented and are shown as mean +/- SEM of triplicate cultures. 
*p<0.05 as determined by 2-way ANOVA with Bonferroni posttests, indicating 
significant differences between T cell stimulatory capacity of DC pre and post anti-TNF 
therapy. (D). T-cells were cultured for 10 days, washed and restimulated with 
CD3/CD28 expander beads. After 72 h supernatants were harvested and cytokine levels 
determined by ELISA. Results on cytokine production by T-cells primed by mature DC 
post anti-TNF! therapy are presented as a percentage of cytokine production by T-cells 
primed by mature DC pre anti-TNF! therapy. The absolute levels of cytokines 
produced by T-cells primed by mature DC pre anti-TNF! therapy were: 2067 ± 1026 
pg/ml IL-10, 17.9 ± 18.1 ng/ml IL-4, 5.8 ± 3.2 ng/ml IFN# and 453 ± 474 pg/ml IL-17. 
Horizontal lines represent median values. NS:  p-values >0.05 as determined by Mann 
Whitney test indicating non-significant differences between T cell cytokine production 
pre and post anti-TNF-therapy. 
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